Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
napabucasin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Sumitomo Pharma
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Napabucasin + paclitaxel is an investigational combination therapy consisting of napabucasin, a first-in-class small molecule cancer stemness inhibitor, and paclitaxel, a well-established microtubule-stabilizing chemotherapeutic agent. Napabucasin acts primarily by inhibiting STAT3-driven gene transcription and spherogenesis in cancer stem cells, thereby targeting tumor cell self-renewal and resistance mechanisms. Paclitaxel disrupts mitosis by stabilizing microtubules. The combination has been studied in multiple advanced solid tumors—including metastatic breast cancer, platinum-resistant ovarian cancer, melanoma, and gastric/gastroesophageal junction (GEJ) adenocarcinoma—based on preclinical evidence of synergistic antitumor activity. Clinical trials have shown the regimen to be generally well tolerated with some encouraging signs of efficacy; however, large phase III studies did not demonstrate significant survival benefit over standard therapies[2][5][6][7][8].
- Other names
- napabucasin + PTXnapabucasin plus paclitaxel
02
Targets
MicrotubuleSTAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on napabucasin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on napabucasin + paclitaxel.